Market Cap 2.12B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 6,823,400
Avg Vol 6,656,706
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 97%
Beta 1.20
Analysts Strong Sell
Price Target $10.75

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
psyxopathis
psyxopathis Aug. 9 at 8:13 PM
$ABCL cant sleep..so anxious about readout tommorow
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 9 at 7:58 PM
$ABCL The optimal course of action with $ABCL for me is to buy a lot more It’ll be a gigantic success
0 · Reply
MarketFractal
MarketFractal Aug. 9 at 7:13 PM
Tomorrow matters for $ABCL. ABCL635 gets its top-line readout before the open, just days after management discussed the program. I’m less interested in the Friday reaction than the actual data. Strong results would give the discovery platform its first real clinical proof and make the rest of the pipeline easier to take seriously.
0 · Reply
EquityResearch6
EquityResearch6 Aug. 9 at 4:42 PM
10 RISK/REWARD PLAYS I’M WATCHING LONG TERM: $QS $RDW $ABCL $SMR $POET Different sectors. Different catalysts. Same idea: High risk. Potentially significant long-term upside. Some are tied to AI infrastructure. Others to fintech, healthcare, energy, aviation, space, batteries, biotech, or photonics. Not every one will work. That’s the point of risk/reward. The goal isn’t to predict every winner. It’s to identify situations where the potential upside is large enough to justify the risk — while managing position size and staying patient. Which one has the best risk/reward? Follow my profile and check my homepage for more high-conviction ideas and long-term opportunities before they become crowded. NFA. DYOR.
0 · Reply
AlphaResearchHQ
AlphaResearchHQ Aug. 9 at 4:07 PM
$ABCL is finally starting to look interesting after clearing that ~$6.50 resistance area. The breakout is holding so far, and price is pushing higher. The next level I’m watching is around $8.40, where I’d expect some profit-taking. If momentum stays strong, the 1.618 Fib area near $8.80 could come into play too. For me, the key is still the 2-day Bull Market Support Band. As long as ABCL stays above it, I don’t see a reason to fight the trend. I’m holding for now, but I’d be willing to trim some around $8.40 rather than getting greedy. If an overbought signal shows up there, I’d probably get a little more defensive. Nothing is guaranteed. I’m just following the levels and adjusting as price gives us more information. No hidden paywall, no complicated access. Just my framework, levels, and how I’m thinking about positioning.
1 · Reply
Odoji
Odoji Aug. 9 at 3:41 PM
$ABCL fomo incoming 💉
0 · Reply
tradersunion353
tradersunion353 Aug. 9 at 2:15 PM
$ABCL time for longs to get rewarded. enough of company and few married to abcl pumpers pumping this real investors i mean who bought stock and expects returns deserve 13 to 15 dollars tomorrow
1 · Reply
MarlonJohn
MarlonJohn Aug. 9 at 1:39 PM
It’s all about the risk-to-reward ratio! 5 disruptive moonshots with insane asymmetrical upside: $SOFI Fintech disrupter coiling up $HIMS High-growth telehealth powerhouse $JOBY eVTOL pioneer leading the air taxi race $QS Solid-state battery holy grail $ABCL AI drug discovery platform Which one runs first? Pinned my full risk-reward sizing guide and targets on my profile page.
0 · Reply
frankitrade
frankitrade Aug. 9 at 1:36 PM
$ABCL Incoming 🚀🚀🚀💰
1 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Aug. 9 at 12:59 PM
$ABCL Not that it makes significant difference, but Im watching the total number of Abcellera followers here. Currently we are sitting at 8,964. Lets see where we end up next week.
0 · Reply
Latest News on ABCL
AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 3 days ago

AbCellera price target raised to $9 from $8 at Stifel


AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026


AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Slides: Q2 2026


AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Earnings release: Q2 2026


AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Quarterly report: Q2 2026


AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 4 days ago

AbCellera Reports Q2 2026 Business Results


AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 4 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 4 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 4 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 3 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 4 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


psyxopathis
psyxopathis Aug. 9 at 8:13 PM
$ABCL cant sleep..so anxious about readout tommorow
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 9 at 7:58 PM
$ABCL The optimal course of action with $ABCL for me is to buy a lot more It’ll be a gigantic success
0 · Reply
MarketFractal
MarketFractal Aug. 9 at 7:13 PM
Tomorrow matters for $ABCL. ABCL635 gets its top-line readout before the open, just days after management discussed the program. I’m less interested in the Friday reaction than the actual data. Strong results would give the discovery platform its first real clinical proof and make the rest of the pipeline easier to take seriously.
0 · Reply
EquityResearch6
EquityResearch6 Aug. 9 at 4:42 PM
10 RISK/REWARD PLAYS I’M WATCHING LONG TERM: $QS $RDW $ABCL $SMR $POET Different sectors. Different catalysts. Same idea: High risk. Potentially significant long-term upside. Some are tied to AI infrastructure. Others to fintech, healthcare, energy, aviation, space, batteries, biotech, or photonics. Not every one will work. That’s the point of risk/reward. The goal isn’t to predict every winner. It’s to identify situations where the potential upside is large enough to justify the risk — while managing position size and staying patient. Which one has the best risk/reward? Follow my profile and check my homepage for more high-conviction ideas and long-term opportunities before they become crowded. NFA. DYOR.
0 · Reply
AlphaResearchHQ
AlphaResearchHQ Aug. 9 at 4:07 PM
$ABCL is finally starting to look interesting after clearing that ~$6.50 resistance area. The breakout is holding so far, and price is pushing higher. The next level I’m watching is around $8.40, where I’d expect some profit-taking. If momentum stays strong, the 1.618 Fib area near $8.80 could come into play too. For me, the key is still the 2-day Bull Market Support Band. As long as ABCL stays above it, I don’t see a reason to fight the trend. I’m holding for now, but I’d be willing to trim some around $8.40 rather than getting greedy. If an overbought signal shows up there, I’d probably get a little more defensive. Nothing is guaranteed. I’m just following the levels and adjusting as price gives us more information. No hidden paywall, no complicated access. Just my framework, levels, and how I’m thinking about positioning.
1 · Reply
Odoji
Odoji Aug. 9 at 3:41 PM
$ABCL fomo incoming 💉
0 · Reply
tradersunion353
tradersunion353 Aug. 9 at 2:15 PM
$ABCL time for longs to get rewarded. enough of company and few married to abcl pumpers pumping this real investors i mean who bought stock and expects returns deserve 13 to 15 dollars tomorrow
1 · Reply
MarlonJohn
MarlonJohn Aug. 9 at 1:39 PM
It’s all about the risk-to-reward ratio! 5 disruptive moonshots with insane asymmetrical upside: $SOFI Fintech disrupter coiling up $HIMS High-growth telehealth powerhouse $JOBY eVTOL pioneer leading the air taxi race $QS Solid-state battery holy grail $ABCL AI drug discovery platform Which one runs first? Pinned my full risk-reward sizing guide and targets on my profile page.
0 · Reply
frankitrade
frankitrade Aug. 9 at 1:36 PM
$ABCL Incoming 🚀🚀🚀💰
1 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Aug. 9 at 12:59 PM
$ABCL Not that it makes significant difference, but Im watching the total number of Abcellera followers here. Currently we are sitting at 8,964. Lets see where we end up next week.
0 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 9 at 12:21 PM
$ABCL If AbCellera’s Phase 2 top-line data for ABCL635 is positive tomorrow, this stock will likely never see single digits again. Let that sink in. $ABCL
0 · Reply
Stockingtrade
Stockingtrade Aug. 9 at 12:12 PM
@SwingTrades1 I'm hoping to send you a private message about $ABCL shorts, please follow me so we can chat.
1 · Reply
snowPOW
snowPOW Aug. 9 at 5:50 AM
$ABCL AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 https://share.google/CQ8h4Ms5QnV98RIr9
0 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 9 at 4:04 AM
$ABCL who did $LLY and Thiel go to during COVID? Not a flash in the pan. Big times, here we come!🚀🚀
1 · Reply
GinoGino
GinoGino Aug. 9 at 2:51 AM
$ABCL The implications of the readout are enormous for the company’s overall pipeline, much bigger than this one drug If the data is solid, I expect 65%+ rise in the initial hours and perhaps days. However, further confirmation and analysts updating their models, this could be a multibagger in the medium- to long-term.
0 · Reply
JennyRowes
JennyRowes Aug. 9 at 2:08 AM
$ABCL curious what people think ABCL635 is worth if data readout meets goal of equal efficacy to approved drugs but with better safety?
3 · Reply
DOGBIRD
DOGBIRD Aug. 9 at 1:45 AM
$ABCL I feel like dilution is coming after SP hike with good data. Wonder how high SP will get to. Crossing fingers.
3 · Reply
PolarBear1
PolarBear1 Aug. 9 at 1:13 AM
0 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Aug. 9 at 1:10 AM
$ABCL As many are trying to guess the share price Mid-Long Term here is simple math: US Addressable Market 6B Annually, lets say we capture 50% of it. That's $3B annual revenue. Assuming 70% Margin we are looking roughly $2B Annual Profit. Take 15 Multiple (conservative) that we are $30B company. From Current share price we are looking at 15X - which is 105$ per share. Now remember - that's US Market only, doesn't take into account everything else that's currently brining in the revenue and the potential for additional drugs. Wait for 5 years and $ABCL $200-$500 stock (conservative)
2 · Reply
SwingTrades1
SwingTrades1 Aug. 9 at 1:02 AM
$ABCL If my thesis is right, we may be seeing an **older short position on one side and a newer, more sophisticated bullish options trade on the other, positioning for the P2 results**. There’s no proof yet that they are different players, but the evidence is starting to point that way. If that turns out to be true and the P2 results are strong, we could potentially see a **decent short squeeze** as the shorts scramble to cover.
1 · Reply
mrpocket
mrpocket Aug. 8 at 11:52 PM
$ABCL Hansen posted…🙄
0 · Reply
PeelonDusk
PeelonDusk Aug. 8 at 9:27 PM
$ABCL At roughly a ~$2B current valuation, $5B is about a 2.5× rerating. For that to become fundamentally defensible, I’d want Monday to show three things simultaneously: a clearly statistically significant and clinically meaningful reduction in hot flashes versus placebo, durability supporting ABCL635’s long-acting/monthly proposition, and a very clean safety profile—particularly no liver signal. I’d frame Monday roughly as: Good data → $2.5–3.5B becomes reasonable Excellent/differentiated data → $4–5B becomes defensible Exceptional data + obvious monthly-dosing advantage → $5B+ becomes conceivable And there’s an asymmetry here: $5B doesn’t require ABCL635 to capture anything close to the entire VMS market. Once randomized Phase 2 efficacy is demonstrated, even a probability-adjusted fraction of a multibillion-dollar commercial opportunity can add substantial value to a company starting around ~$2B.
2 · Reply